Bone metastases of thyroid tumors should be treated with bisphosphonates
Clinical Thyroidology
Bisphosphonates are increasingly being used to delay the growth of bone metastases in a number of cancers, such as in malignant tumors of the lung, breast, prostate, and kidney and in multiple myeloma. They have also been reported to be of value in metastatic thyroid cancer, but most reports include only a small number of cases. Bisphosphonates inhibit osteoclastic bone resorption, and in the cancers mentioned above bisphosphonates are able to decrease the release of markers of bone resorption such as pyridinoline-cross-linked carboxy terminal telopeptide.More

Hashimoto's thyroiditis affects symptom load and quality of life unrelated to hypothyroidism: A prospective case - control study in women undergoing thyroidectomy for benign goiter
Thyroid
Hashimoto's thyroiditis (HT) is a common disease, and is the most prevalent cause of hypothyroidism. Symptoms and diseases associated with HT are considered to be caused by hypothyroidism. We hypothesized that higher antithyroperoxidase (anti-TPO) antibody levels would be associated with an increased symptom load and a decreased quality of life in a female euthyroid patient collective.More

Imaging in thyroid cancer patients with spread of the cancer outside of the neck
Clinical Thyroidology for Patients
The vast majority of patients diagnosed with thyroid cancer do very well. Most are cured of their cancer through a combination of surgery and radioactive iodine, which is taken up by the cancer to destroy it. While overall death from thyroid cancer is rare, the prognosis of thyroid cancer patients with spread of the cancer outside of the neck is less favorable. This is especially true for patients over the age of 45 or if the cancer does not take up radioactive iodine. FDG-PET scans use a small amount of radioactive glucose (FDG) to identify cancer and have been used to predict prognosis in other cancers. This study examined whether FDG-PET scans can be used as a prognostic factor in thyroid cancer patients with spread of the cancer outside of the neck.More

Does placental iodine storage compensate for low maternal iodine intake?
Clinical Thyroidology
The authors' objective is to compare the iodine content of placentas from women giving birth at term in Ireland and Iran, areas with a median urinary iodine (UI) of 79 µg/L and 206 µg/L, respectively. Controversy exists about the role of the placenta in transferring to the fetus iodine ingested by the mother. Although there is evidence of subclinical hypothyroidism or hypothyroxinemia in children born to women with borderline to low dietary iodine intake as assessed by urinary iodine excretion, the majority of mothers and infants show no ill effects from moderate iodine deficiency.More

Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131-I: Practice recommendations of the American Thyroid Association
Thyroid
Radiation safety is an essential component in the treatment of patients with thyroid diseases by 131-I. The American Thyroid Association created a task force to develop recommendations that would inform medical professionals about attainment of radiation safety for patients, family members, and the public. The task force was constituted so as to obtain advice, experience, and methods from relevant medical specialties and disciplines.More